ReShape Lifesciences Ownership

RSLS Stock  USD 3.18  0.33  11.58%   
ReShape Lifesciences holds 10.62 pct. of its outstanding shares held by insiders and 0.72 pct. owned by third-party entities.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

ReShape Stock Ownership Analysis

The company recorded earning per share (EPS) of 264.12. ReShape Lifesciences last dividend was issued on the 25th of July 2019. The entity had 1:25 split on the 9th of May 2025. ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. Reshape Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 47 people. To find out more about ReShape Lifesciences contact Dan Gladney at 949 429 6680 or learn more at https://www.reshapelifesciences.com.

ReShape Lifesciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ReShape Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ReShape Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ReShape Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Schneid Yair over a month ago
Disposition of tradable shares by Schneid Yair of ReShape Lifesciences subject to Rule 16b-3
 
Thomas Stankovich over three months ago
Disposition of 157 shares by Thomas Stankovich of ReShape Lifesciences at 13.29 subject to Rule 16b-3
 
Armistice Capital, Llc over three months ago
Acquisition by Armistice Capital, Llc of tradable shares of ReShape Lifesciences subject to Rule 16b-3
 
Armistice Capital, Llc over three months ago
Acquisition by Armistice Capital, Llc of 1479713 shares of ReShape Lifesciences at 6.0 subject to Rule 16b-3
 
Thomas Stankovich over six months ago
Disposition of 109 shares by Thomas Stankovich of ReShape Lifesciences at 2.6 subject to Rule 16b-3
 
Bandy Barton P. over six months ago
Disposition of 11674 shares by Bandy Barton P. of ReShape Lifesciences at 0.47 subject to Rule 16b-3
 
Thomas Stankovich over six months ago
Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 7.49 subject to Rule 16b-3
 
Thomas Stankovich over six months ago
Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.17 subject to Rule 16b-3
 
Bandy Barton P. over six months ago
Disposition of 2699 shares by Bandy Barton P. of ReShape Lifesciences at 0.96 subject to Rule 16b-3
 
Thomas Stankovich over six months ago
Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.25 subject to Rule 16b-3
 
Thomas Stankovich over six months ago
Acquisition by Thomas Stankovich of 1000 shares of ReShape Lifesciences at 0.9 subject to Rule 16b-3
 
Minocherhomjee Arda Phd over six months ago
Insider Trading

ReShape Lifesciences Outstanding Bonds

ReShape Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ReShape Lifesciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ReShape bonds can be classified according to their maturity, which is the date when ReShape Lifesciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.